Latest News and Press Releases

Over 20 years of leadership experience in the biopharmaceutical industryFormer Vice President and General Manager, U.S. Prescription Business for GaldermaFormer Head of Pfizer’s U.S. Pharmaceutical...

JT and its subsidiary, Torii Pharmaceutical, receive rights to develop and commercialize tapinarof for psoriasis and atopic dermatitis in Japan Dermavant to receive an upfront payment of $60 million,...

Phase 2a clinical trial for topical cerdulatinib to enroll 30 patients with vitiligoTop-line results anticipated in second half of 2020 BASEL, Switzerland and LONG BEACH, Calif., Dec. 03, 2019 ...

Top-line data is anticipated in the first half of 2020If PSOARING trials are successful, a New Drug Application (NDA) filing with the U.S. Food and Drug Administration (FDA) is anticipated in 2021 ...

LONDON, May 15, 2019 (GLOBE NEWSWIRE) -- Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that Timothy S. Nelson and Kenneth E. Ludlum have been appointed to...

Mr. Allouche has over 20 years of combined experience in finance leadership, audit, and advisory roles, most recently serving as Principal Accounting Officer, Head of Finance, and Corporate Controller...

Dermavant plans to initiate Phase 3 clinical program evaluating tapinarof for the treatment of psoriasis in the first half of 2019 BASEL, Switzerland and PHOENIX, Feb. 21, 2019 (GLOBE NEWSWIRE) --...

Dr. Brown previously served as Head of Global Pharmaceutical Development at Galderma and has over 25 years of experience leading clinical development programsDermavant plans to initiate Phase 3...

BASEL, Switzerland, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the company will present new data on cerdulatinib...

BASEL, Switzerland, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that two abstracts containing Phase 2b data on...